Specifically targeting HER2 surface receptors, an EGFR-class protein found in aggressive breast cancers, is an area that is being actively investigated with the aim of offering diagnostic and treatment solutions for certain malignancies. The gene discussed is EGFR; the disease is breast carcinoma.